Skip to content

A Study to Evaluate the Safety and Effectiveness of the Technols 217z Zyoptix System for Hyperopia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00348205
Enrollment
80
Registered
2006-07-04
Start date
2005-06-30
Completion date
2009-03-31
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Astigmatism, Hyperopia

Brief summary

A study to demonstrate the safety and effectiveness of wavefront laser refractive surgery treatments for hyperopia and astigmatism.

Interventions

DEVICETechnolas 217z Zyoptix Laser

Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software for the wavefront-guided LASIK treatment of hyperopia and hyperoptic astigmatism.

Sponsors

Bausch & Lomb Incorporated
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Hyperopia with or without astigmatism.

Exclusion criteria

* Contraindications to LASIK.

Design outcomes

Primary

MeasureTime frameDescription
The Percentage of Eyes With a Postoperative Subjective Manifest Refraction Spherical Equivalent (MRSE) Within ± 1.00 Diopter (D) and ± 0.50 D of Emmetropia24 monthsManifest refractions (eyeglass prescriptions) have three components: sphere, cylinder, and axis. Sphere and cylinder are both expressed in diopters, which is a continuous measure of the focusing power needed to make the image sharp on the retina. Manifest refraction spherical equivalent (MRSE) is equal to sphere + ½ x cylinder. It is expressed in diopters (D).
Percentage of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better at 12 Months and 24 Months24 months
Percentage of Eyes With a Postoperative Subjective Manifest Refraction Spherical Equivalent (MRSE) Within ± 1.00 Diopter (D) and ± 0.50 D of Emmetropia.12 monthsManifest refractions (eyeglass prescriptions) have three components: sphere, cylinder, and axis. Sphere and cylinder are both expressed in diopters, which is a continuous measure of the focusing power needed to make the image sharp on the retina. Manifest refraction spherical equivalent (MRSE) is equal to sphere + ½ x cylinder. It is expressed in diopters (D).
Induced Astigmatism24 monthsPercentage of eyes which had \>2.00 Diopter of induced refractive cylinder for those eyes treated for spherical hyperopia only.
Refractive Stability - Categorical Change Between Month 1 and Month 3Month 1, Month 3Percentage of eyes with a change of ≤ 1.00 Diopter in manifest refraction spherical equivalent (MRSE) between postoperative refractions, performed at 1 months and 3 months after surgery. Manifest refractions (eyeglass prescriptions) have three components: sphere, cylinder, and axis. Sphere and cylinder are both expressed in diopters, which is a continuous measure of the focusing power needed to make the image sharp on the retina. Manifest refraction spherical equivalent (MRSE) is equal to sphere + ½ x cylinder. It is expressed in diopters (D).
Refractive Stability - Mean Change Between Month 1 and Month 31 month, 3 monthsMean change in manifest refraction spherical equivalent (MRSE) between postoperative refractions, performed at 1 months and 3 months after surgery. Manifest refractions (eyeglass prescriptions) have three components: sphere, cylinder, and axis. Sphere and cylinder are both expressed in diopters, which is a continuous measure of the focusing power needed to make the image sharp on the retina. Manifest refraction spherical equivalent (MRSE) is equal to sphere + ½ x cylinder. It is expressed in diopters (D).

Secondary

MeasureTime frameDescription
Loss of Best Spectacle-corrected Visual Acuity (BSCVA)24 monthsPercentage of eyes with loss of best spectacle corrected visual acuity (BSCVA) of \>2 lines. Mean change in best-corrected high contrast distance visual acuity. Corrected means spectacle corrected. Visual acuity (VA) was reported as letters read correctly, and the letters read were converted to logarithm of the minimum angle of resolution (logMAR) acuity. The participant read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters. The total number of correct letters were recorded. A decrease in the number of correct letters indicates a decrease in visual acuity. Acuity was averaged across visits.

Countries

United States

Participant flow

Participants by arm

ArmCount
Technolas 217z Zyoptix System
Bausch & Lomb Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software. Technolas 217z Zyoptix Laser: Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software for the wavefront-guided LASIK treatment of hyperopia and hyperoptic astigmatism.
80
Technolas 217z Zyoptix System
Bausch & Lomb Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software. Technolas 217z Zyoptix Laser: Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software for the wavefront-guided LASIK treatment of hyperopia and hyperoptic astigmatism.
159
Total239

Baseline characteristics

CharacteristicTechnolas 217z Zyoptix System
Age, Continuous49.5 years
STANDARD_DEVIATION 8.7
Sex: Female, Male
Female
45 Participants
Sex: Female, Male
Male
35 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 80
other
Total, other adverse events
0 / 80
serious
Total, serious adverse events
1 / 80

Outcome results

Primary

Induced Astigmatism

Percentage of eyes which had \>2.00 Diopter of induced refractive cylinder for those eyes treated for spherical hyperopia only.

Time frame: 24 months

Population: There were 32 sphere eyes assessed for this outcome measure.

ArmMeasureValue (COUNT_OF_UNITS)
Technolas 217z Zyoptix SystemInduced Astigmatism0 eyes
Primary

Percentage of Eyes With a Postoperative Subjective Manifest Refraction Spherical Equivalent (MRSE) Within ± 1.00 Diopter (D) and ± 0.50 D of Emmetropia.

Manifest refractions (eyeglass prescriptions) have three components: sphere, cylinder, and axis. Sphere and cylinder are both expressed in diopters, which is a continuous measure of the focusing power needed to make the image sharp on the retina. Manifest refraction spherical equivalent (MRSE) is equal to sphere + ½ x cylinder. It is expressed in diopters (D).

Time frame: 12 months

Population: The number of eyes available for manifest refraction spherical equivalent assessment at 12 months were included in the analysis.

ArmMeasureGroupValue (COUNT_OF_UNITS)
Technolas 217z Zyoptix SystemPercentage of Eyes With a Postoperative Subjective Manifest Refraction Spherical Equivalent (MRSE) Within ± 1.00 Diopter (D) and ± 0.50 D of Emmetropia.Within 0.50 D100 eyes
Technolas 217z Zyoptix SystemPercentage of Eyes With a Postoperative Subjective Manifest Refraction Spherical Equivalent (MRSE) Within ± 1.00 Diopter (D) and ± 0.50 D of Emmetropia.Within 1.00 D142 eyes
Primary

Percentage of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better at 12 Months and 24 Months

Time frame: 24 months

Population: The number of eyes available for uncorrected visual acuity assessment at 12 months and 24 months were included in the analysis.

ArmMeasureGroupValue (COUNT_OF_UNITS)
Technolas 217z Zyoptix SystemPercentage of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better at 12 Months and 24 Months12 months147 eyes
Technolas 217z Zyoptix SystemPercentage of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better at 12 Months and 24 Months24 months140 eyes
Primary

Refractive Stability - Categorical Change Between Month 1 and Month 3

Percentage of eyes with a change of ≤ 1.00 Diopter in manifest refraction spherical equivalent (MRSE) between postoperative refractions, performed at 1 months and 3 months after surgery. Manifest refractions (eyeglass prescriptions) have three components: sphere, cylinder, and axis. Sphere and cylinder are both expressed in diopters, which is a continuous measure of the focusing power needed to make the image sharp on the retina. Manifest refraction spherical equivalent (MRSE) is equal to sphere + ½ x cylinder. It is expressed in diopters (D).

Time frame: Month 1, Month 3

Population: There were 139 eyes with manifest refraction spherical equivalent assessments at both Month 1 and Month 3 for this outcome assessment.

ArmMeasureValue (COUNT_OF_UNITS)
Technolas 217z Zyoptix SystemRefractive Stability - Categorical Change Between Month 1 and Month 3135 eyes
Primary

Refractive Stability - Mean Change Between Month 1 and Month 3

Mean change in manifest refraction spherical equivalent (MRSE) between postoperative refractions, performed at 1 months and 3 months after surgery. Manifest refractions (eyeglass prescriptions) have three components: sphere, cylinder, and axis. Sphere and cylinder are both expressed in diopters, which is a continuous measure of the focusing power needed to make the image sharp on the retina. Manifest refraction spherical equivalent (MRSE) is equal to sphere + ½ x cylinder. It is expressed in diopters (D).

Time frame: 1 month, 3 months

Population: There were 139 eyes with manifest refraction spherical equivalent assessments at both Month 1 and Month 3 for this outcome assessment.

ArmMeasureValue (MEAN)Dispersion
Technolas 217z Zyoptix SystemRefractive Stability - Mean Change Between Month 1 and Month 30.12 diopterStandard Deviation 0.4
Primary

The Percentage of Eyes With a Postoperative Subjective Manifest Refraction Spherical Equivalent (MRSE) Within ± 1.00 Diopter (D) and ± 0.50 D of Emmetropia

Manifest refractions (eyeglass prescriptions) have three components: sphere, cylinder, and axis. Sphere and cylinder are both expressed in diopters, which is a continuous measure of the focusing power needed to make the image sharp on the retina. Manifest refraction spherical equivalent (MRSE) is equal to sphere + ½ x cylinder. It is expressed in diopters (D).

Time frame: 24 months

Population: The number of eyes available for manifest refraction spherical equivalent assessment at 24 months were included in the analysis.

ArmMeasureGroupValue (COUNT_OF_UNITS)
Technolas 217z Zyoptix SystemThe Percentage of Eyes With a Postoperative Subjective Manifest Refraction Spherical Equivalent (MRSE) Within ± 1.00 Diopter (D) and ± 0.50 D of EmmetropiaWithin 0.50 D97 eyes
Technolas 217z Zyoptix SystemThe Percentage of Eyes With a Postoperative Subjective Manifest Refraction Spherical Equivalent (MRSE) Within ± 1.00 Diopter (D) and ± 0.50 D of EmmetropiaWithin 1.00 D129 eyes
Secondary

Loss of Best Spectacle-corrected Visual Acuity (BSCVA)

Percentage of eyes with loss of best spectacle corrected visual acuity (BSCVA) of \>2 lines. Mean change in best-corrected high contrast distance visual acuity. Corrected means spectacle corrected. Visual acuity (VA) was reported as letters read correctly, and the letters read were converted to logarithm of the minimum angle of resolution (logMAR) acuity. The participant read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters. The total number of correct letters were recorded. A decrease in the number of correct letters indicates a decrease in visual acuity. Acuity was averaged across visits.

Time frame: 24 months

Population: The number of eyes available for uncorrected visual acuity assessment at 12 months and 24 months were included in the analysis.

ArmMeasureGroupValue (COUNT_OF_UNITS)
Technolas 217z Zyoptix SystemLoss of Best Spectacle-corrected Visual Acuity (BSCVA)12 months1 eyes
Technolas 217z Zyoptix SystemLoss of Best Spectacle-corrected Visual Acuity (BSCVA)24 months3 eyes

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026